Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Mesothelioma
Results 1-25 of 56 for your search:
Start Over
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: POLARIS2015-003, NCI-2017-00005, NCT02709512
Nintedanib (BIBF 1120) in Mesothelioma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.93, NCI-2013-01643, 2012-005201-48, NCT01907100
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-743, NCI-2016-01557, 2016-001859-43, NCT02899299
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, 348360, P131392, NCT02054104
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA008-002, NCI-2015-01329, 2014-002485-70, NCT02341625
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0152, NCI-2016-01247, P152145, NCT02859415
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Sym013-01, NCI-2016-01802, NCT02906670
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TL139204, NCI-2015-00076, NCT00685204
Surgery, Chemotherapy, and Intensity Modulated Radiation Therapy in Treating Patients with Stage I-III Pleural Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 08-053, NCI-2016-01016, NCT00715611
Erlotinib Hydrochloride in Treating Patients with Malignant Peritoneal Mesothelioma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0032, NCI-2012-00332, NCT01592383
Plicamycin in Treating Patients with Malignancies Involving the Lungs, Esophagus, or Pleura That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0151, NCI-2013-01534, 120151, P12961, NCT01624090
Dendritic Cell Vaccine, Recombinant Interferon Alfa, Rintatolimod, and Celecoxib After Surgery in Treating Patients with Peritoneal Surface Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 12-110, NCI-2014-01357, 02151448, NCT02151448
Chemotherapy With or Without Porfimer Sodium-Based Photodynamic Therapy During Surgery in Treating Patients With Malignant Pleural Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 14513, NCI-2014-01242, 819186, NCT02153229
Alisertib in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 2014-0497, NCI-2014-02568, X14024, NCT02293005
Pembrolizumab in Treating Patients with Malignant Mesothelioma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-1381, NCI-2015-00348, NCT02399371
Nintedanib and Prednisone in Reducing Radiation-Induced Pneumonitis in Patients with Thoracic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 14-167, NCI-2015-01232, NCT02496585
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18094, NCI-2016-00002, NCT02611037
Nintedanib in Treating Patients with Malignant Pleural Mesothelioma That Is Recurrent or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-010, NCI-2015-01412, 1506014121, NCT02568449
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Start Over